CJC-1295
CJC-1295
CJC-1295 (/siːdʒeɪsiː/ /wʌn/ /tuː/ /naɪn/ /faɪv/) is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue made up of 30 amino acids. It has been found to be effective in increasing growth hormone and IGF-1 levels, and its benefits include longer binding time to the Growth Hormone Receptor which results in an overall increase in growth hormone.
Etymology
The term "CJC-1295" is derived from the initials of the ConjuChem Biotechnologies company that first synthesized this peptide, with "1295" being an arbitrary sequence number.
Usage
CJC-1295 is typically provided in vials containing 2 or 5 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.
Side Effects
As with any peptide, there are potential side effects from using CJC-1295. These can include: mild irritation at the injection site, flushing, headache and dizziness. These side effects are typically mild and subside quickly. More serious side effects can include: an allergic reaction (hives, difficulty breathing, swelling of the face, lips, tongue, or throat), chest pain, dark urine, and irregular heartbeat.
Related Terms
External links
- Medical encyclopedia article on CJC-1295
- Wikipedia's article - CJC-1295
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski